Predictive Oncology Inc. — Q3 2022 Form 10-Q
Identity note: The request metadata names Axe Compute Inc., but the supplied filing is for Predictive Oncology Inc. (Nasdaq: POAI). Confirm the intended company before relying on this summary. The filing covers the quarter and nine months ended September 30, 2022; it was filed November 10, 2022.
Business context and financial position
Predictive Oncology operates four business areas: Helomics (oncology testing and contract research), zPREDICTA (tumor-specific models and research), Soluble (biologics formulation services), and Skyline (STREAMWAY medical fluid-waste systems). Management said it intended to focus resources on Helomics and zPREDICTA.
- At September 30, cash and cash equivalents were $25.4 million, versus $28.2 million at December 31, 2021. Total assets were $33.2 million, down from $43.8 million.
- Total liabilities were $3.6 million, including $3.5 million current liabilities. The company reported no outstanding debt. Current assets of $26.9 million substantially exceeded current liabilities.
- Stockholders’ equity was $29.6 million, down from $40.3 million; accumulated deficit was $145.9 million.
- Common shares outstanding increased to 78.4 million from 65.6 million at year-end. The filing reports 78.8 million shares outstanding as of November 4, 2022.
Revenue, results, and cash flows
- Q3 revenue: $455,827, up 45% from $313,663 in Q3 2021. Net loss was $4.06 million, compared with $5.44 million; loss per share was $0.05 versus $0.08.
- Nine-month revenue: $1.14 million, up 21% from $944,187. Net loss widened to $17.82 million from $11.90 million; loss per share was $0.25 versus $0.23.
- Gross profit was $347,676 in Q3 and $790,317 for the nine months. Gross margin was approximately 76% in Q3 and 69% year to date, versus 65% in each prior-year comparison. Management attributed the Q3 improvement to a larger contribution from zPREDICTA CRO services; year-to-date margin was affected by higher disposable-related costs.
- Nine-month operating expenses included a $7.23 million goodwill impairment relating to zPREDICTA; the comparable 2021 period included a $2.81 million impairment relating to Helomics. Excluding these unusual charges, operating expenses still rose, notably in operations and sales and marketing.
- Cash used in operations was $9.14 million for the nine months, up from $8.46 million. Investing activities used $412,096; financing provided $6.74 million, principally from the May 2022 stock-and-warrant offering. Cash declined by $2.81 million over the period.
Changes, outlook, and risks
- The May 2022 offerings issued 12.0 million shares at $0.60 per share and generated $6.51 million in net proceeds. Existing warrants covering approximately 16.3 million shares were repriced to $0.70 and had their terms extended; additional warrant issuance and possible exercises create dilution risk.
- Management said existing capital resources were expected to support the operating plan for the next 12 months and beyond. It also said it may seek additional debt, equity, or other financing; access to the remaining $8.88 million equity-line balance was restricted until May 18, 2023, and further equity issuance would be dilutive.
- The company continued to report operating losses and negative operating cash flow. Management cited uncertainty around revenue generation, future financing availability, acquisitions and potential impairments, competition, regulation, key personnel, and COVID-related supplier and sales disruptions. No specific revenue or earnings guidance was provided.
- CEO J. Melville Engle announced retirement effective October 31, 2022. The transition agreement provided for $524,400 severance, a $139,000 prorated bonus, and accelerated vesting of 300,000 restricted stock units; $741,505 was accrued at September 30.
- Disclosure controls were deemed ineffective due to a material weakness involving insufficient accounting resources and expertise for complex U.S. GAAP matters. The company reported hiring additional resources but had not yet concluded that the weakness was remediated.
- COVID-19-related supplier relocation had delayed STREAMWAY parts and order fulfillment. The filing also disclosed a $6.51 million cash balance at one institution above FDIC-insured limits.
Key facts investors should verify
- Confirm the filing’s registrant is Predictive Oncology Inc., not Axe Compute Inc.
- Assess whether cash and the stated financing plan can sustain operations given the $9.14 million nine-month operating cash outflow and low revenue base.
- Review the assumptions behind the $7.23 million zPREDICTA goodwill impairment and the corrected acquisition accounting for contract liabilities.
- Evaluate dilution from the 2022 share issuance, repriced and extended warrants, and any future equity-line or capital raises.
- Check subsequent filings for CEO transition completion, material-weakness remediation, and evidence of revenue growth—particularly in Helomics and zPREDICTA.